Getinge Group

Getinge Group, legally associated with Getinge AB, is a Swedish medical-technology company whose products are used in hospitals, intensive-care units, operating rooms, sterilization departments, and life-science manufacturing environments. The company began in 1904 in the Swedish town of Getinge as an agricultural enterprise founded by Olander Larsson. During the 1930s it expanded into medical technology, creating the basis for the healthcare-focused business that later developed through acquisitions and organizational changes. The modern group operates through three principal business areas: Life Science, Acute Care Therapies, and Surgical Workflows. Life Science supplies equipment and systems used in pharmaceutical, biotechnology, and laboratory production environments. Acute Care Therapies addresses critical-care and intensive-care needs, including ventilators and related technologies. Surgical Workflows covers equipment and infrastructure used before, during, and after surgery, including operating-room systems, sterilization, and infection-prevention solutions. The portfolio is aimed primarily at institutional customers rather than consumers, and the business is commonly positioned around improving clinical workflows, patient care, infection control, and the efficiency of healthcare and life-science operations. Getinge became part of Electrolux in 1964 and was subsequently strengthened through acquisitions. In 1989, former Electrolux managers Rune Andersson and Carl Bennet acquired the company. Getinge was taken public in 1993 in a transaction valued at approximately SEK 600 million. Carl Bennet has remained the dominant shareholder through Carl Bennet AB, holding a substantial proportion of the capital and a majority of the voting rights according to the referenced company history. Getinge was included in the OMXS30 index from July 2009 through June 2025. Acquisitions have been central to the group’s development. Notable transactions include the purchase of Maquet GmbH in 2000, Heraeus Med in 2002, Huntleigh Technology in 2007, Atrium Medical in 2011, and Pulsion Medical Systems in 2014. More recent expansion included Healthmark Industries in 2023 and Paragonix Technologies in 2024. These transactions broadened Getinge’s presence in surgical workflows, infection prevention, cardiovascular and critical-care applications, and adjacent medical technologies. The United States is Getinge’s most important market, representing approximately 40 percent of sales in the referenced description, partly because prices and margins are higher there than in many other regions. China and Western European countries are also significant markets. The group employs approximately 12,000 people worldwide. Mattias Perjos serves as chief executive officer and Johan Malmquist as chair of the board in the referenced material. Getinge has also faced regulatory and legal challenges. The United States Food and Drug Administration ordered recalls involving two Getinge products in 2023 because of identified risks. The company has additionally reached settlements relating to alleged defects in surgical products in the United States and alleged unfair competition in Brazil. These matters illustrate the regulatory exposure associated with supplying safety-critical hospital equipment. In 2025, Getinge expanded its Servo-c ventilator offering to neonatal care, with a design intended to support preterm infants weighing as little as 500 grams.

Getinge’s origins date to 1904, when Olander Larsson established an agricultural company in Getinge, Sweden. The business moved into medical technology during the 1930s, beginning a long transition from agricultural machinery and equipment toward healthcare products. In 1964, Electrolux acquired the company. Under Electrolux ownership, Getinge was developed and expanded, including through acquisitions that increased its reach in medical technology. A decisive change came in 1989, when former Electrolux managers Rune Andersson and Carl Bennet acquired Getinge. Their ownership provided the foundation for the independently controlled group that later became one of Sweden’s significant medical-technology companies. Getinge was listed on the Stockholm Stock Exchange in 1993 in a transaction valued at approximately SEK 600 million. Carl Bennet subsequently became the company’s principal owner through Carl Bennet AB. The company was included in the OMXS30 index from July 2009 until June 2025. Growth after the listing relied heavily on acquisitions. Getinge purchased the German company Maquet GmbH in 2000, adding important surgical and hospital-equipment capabilities. Heraeus Med followed in 2002, while the acquisition of Huntleigh Technology in 2007 expanded the group’s medical-technology activities. In 2011, Getinge acquired the United States company Atrium Medical. The 2014 purchase of German company Pulsion Medical Systems further broadened its critical-care and monitoring-related portfolio. More recent transactions included Healthmark Industries in 2023 and Paragonix Technologies in 2024, continuing the group’s strategy of building a broader healthcare-technology platform. The group is organized around Life Science, Acute Care Therapies, and Surgical Workflows. This structure reflects the company’s two principal customer environments: healthcare delivery and regulated life-science production. Acute Care Therapies includes technologies for intensive and critical care, including ventilators. Surgical Workflows encompasses technologies and systems used in operating rooms, sterilization, and related hospital processes. Life Science serves pharmaceutical, biotechnology, and laboratory users. Getinge’s business is international, with the United States described as its largest market and accounting for around 40 percent of sales. China and Western Europe are also important regions. The company employs approximately 12,000 people worldwide. Its international scale exposes it to complex medical-device regulation, procurement systems, reimbursement conditions, and product-liability requirements. The company’s history has included substantial legal and regulatory scrutiny. In 2023, the United States Food and Drug Administration ordered recalls involving two Getinge products because of significant risks. Getinge also agreed to a United States settlement of approximately SEK 200 million concerning a class-action lawsuit over alleged defects in surgical products. In Brazil, the company agreed to a settlement of approximately SEK 360 million following allegations of unfair competition relating to the period from 2004 to 2017. In 2025, Getinge expanded the Servo-c ventilator platform for neonatal use. The new design was described as capable of supporting preterm infants weighing as little as 500 grams, extending the company’s acute-care portfolio into a particularly specialized and safety-sensitive patient population.

1. 2025Servo-c neonatal expansion

   Getinge expanded Servo-c ventilator use to neonatal patients, including very-low-weight preterm infants.

   Source
2. 2024Acquisition of Paragonix Technologies

   Getinge acquired United States medical-technology company Paragonix Technologies.

   Source
3. 2023Acquisition of Healthmark Industries

   Getinge acquired Healthmark Industries in the United States.

   Source
4. 2014Acquisition of Pulsion Medical Systems

   The acquisition of German company Pulsion Medical Systems strengthened Getinge’s critical-care and medical-technology activities.

   Source
5. 2011Acquisition of Atrium Medical

   Getinge acquired the United States company Atrium Medical.

   Source
6. 2007Acquisition of Huntleigh Technology

   The purchase of Huntleigh Technology PLC broadened the group’s healthcare product portfolio.

   Source
7. 2002Acquisition of Heraeus Med

   Getinge acquired Heraeus Med as part of its continuing expansion through medical-technology acquisitions.

   Source
8. 2000Acquisition of Maquet GmbH

   The acquisition of German medical-technology company Maquet expanded Getinge’s surgical and hospital-equipment capabilities.

   Source
9. 1993Stock-market listing

   Getinge became publicly listed in Stockholm in a transaction valued at approximately SEK 600 million.

   Source
10. 1989Acquired by Rune Andersson and Carl Bennet

    Former Electrolux managers Rune Andersson and Carl Bennet acquired the company.

    Source
11. 1964Acquired by Electrolux

    Electrolux acquired Getinge and subsequently supported its development through further acquisitions.

    Source
12. 1930Expansion into medical technology

    The company began expanding from agricultural activities into medical technology during the 1930s.

    Source
13. 1904Company founded in Getinge, Sweden

    Olander Larsson founded the original agricultural company in the Swedish town of Getinge.

    Source

A global business-to-business medical-technology supplier focused on acute care, surgical workflows, infection prevention, and life-science production. Getinge positions its portfolio as infrastructure and clinical technology for hospitals and regulated life-science organizations rather than as a consumer medical brand.

• Servo ventilatorsAcute care and neonatal ventilation

  The Servo platform is Getinge’s ventilator family for intensive and acute care. The products are intended for mechanically supporting patients whose breathing requires clinical assistance. In 2025, Getinge expanded Servo-c use to neonatal care, with the referenced design intended to support preterm infants weighing as little as 500 grams. Specific model availability and regulatory indications vary by market.

• Surgical Workflow systemsOperating-room and surgical infrastructure

  Getinge’s Surgical Workflows portfolio covers equipment and systems intended to connect operating-room activities with broader hospital processes. The area includes technologies associated with surgical environments, operating-room infrastructure, and workflow coordination. The portfolio was materially strengthened by the company’s acquisition of Maquet and other medical-technology businesses.

• Sterilization and infection-prevention solutionsHospital hygiene and sterile processing

  These products support hospitals in cleaning, sterilizing, and managing reusable medical instruments and related workflows. They are used by sterile-processing and infection-prevention teams rather than by consumers. The area is connected to Getinge’s hospital-systems activities and was further developed through acquisitions including Healthmark Industries.

• Life Science equipment and systemsPharmaceutical and biotechnology manufacturing

  The Life Science business supplies equipment and systems for pharmaceutical, biotechnology, laboratory, and other regulated production environments. Its role is to support controlled processing and manufacturing workflows where sterility, repeatability, and regulatory compliance are important. The referenced material does not identify individual product models.

• Acute Care Therapies portfolioCritical-care medical technology

  Acute Care Therapies brings together technologies used in intensive-care and other high-acuity clinical settings. Ventilators are a prominent part of the portfolio, alongside related technologies acquired or developed for critical-care environments. Products are sold to healthcare institutions and are subject to market-specific medical-device regulation.

• 2025Expansion of Servo-c into neonatal careProduct launch

  Neonatal ventilation requires equipment designed for extremely small and vulnerable patients.

  What changed. Getinge expanded its Servo-c ventilator offering to neonatal patients, including preterm infants weighing approximately 500 grams.

  Aftermath. The move extended the Servo platform into a more specialized acute-care segment.

  Source
• 2024Acquisition of Paragonix TechnologiesM&A

  Getinge used acquisitions to extend its United States medical-technology presence.

  What changed. The company acquired Paragonix Technologies.

  Aftermath. Paragonix became part of Getinge’s broader healthcare-technology portfolio.

  Source
• 2023Acquisition of Healthmark IndustriesM&A

  Getinge continued expanding in the United States and in hospital infection-prevention workflows.

  What changed. The group acquired Healthmark Industries.

  Aftermath. The transaction broadened Getinge’s United States healthcare portfolio.

  Source
• 2000Acquisition of Maquet GmbHM&A

  Getinge pursued acquisitions to broaden its medical-technology portfolio and international reach.

  What changed. The group acquired German company Maquet GmbH.

  Aftermath. Maquet became an important contributor to Getinge’s surgical and hospital-equipment activities.

  Source
• 1993Stockholm public listingStrategy

  Following the 1989 ownership change, Getinge sought access to public capital and a broader shareholder base.

  What changed. The company listed on the Stockholm Stock Exchange in a transaction valued at approximately SEK 600 million.

  Aftermath. The listing provided the corporate platform for continued acquisition-led development.

  Transaction value. SEK 600 million (1993)

  Source
• 1989Return to independent ownershipStrategy

  After a period under Electrolux ownership, former Electrolux managers Rune Andersson and Carl Bennet acquired Getinge.

  What changed. The buyers established a new ownership structure that later supported independent expansion and public listing.

  Aftermath. Carl Bennet remained the principal owner through Carl Bennet AB, while the group expanded through acquisitions and international operations.

  Source

• 2023United States product recallsControversy

  The United States Food and Drug Administration ordered recalls involving two Getinge products because of significant risks. The available reference does not identify the product names or provide further technical details.

  Source
• United States surgical-product class-action settlementControversy

  Getinge agreed to pay approximately SEK 200 million to settle a United States class-action lawsuit concerning alleged defects in surgical products. The available reference does not provide the settlement date or identify the specific products.

  Source
• Brazilian unfair-competition settlementControversy

  Getinge agreed to a settlement of approximately SEK 360 million with Brazilian authorities following allegations of unfair competition relating to conduct between 2004 and 2017.

  Source

• 2025Getinge expands Servo-c ventilator use to neonatal patients

  Getinge expanded its Servo-c ventilator offering for neonatal care, including support for preterm infants weighing approximately 500 grams.

  Product launchProduct generation
  Source
• 2024Getinge acquires Paragonix Technologies

  Getinge completed a major acquisition of the United States medical-technology company Paragonix Technologies, extending its portfolio through an adjacent healthcare technology business.

  M&A
  Source
• 2023Getinge acquires Healthmark Industries

  Getinge acquired Healthmark Industries in the United States, strengthening its position in products associated with infection prevention and healthcare workflows.

  M&A
  Source

1. Getinge Group